Yuelei Shen

I founded Biocytogen in the United States in 2008 and subsequently established Biocytogen Pharmaceuticals (Beijing) Co, Ltd in Beijing, China, in 2009.

By leveraging the advanced capabilities of our proprietary fully human antibody RenMice models (RenMab, RenLite, and RenNano), Biocytogen has emerged as a pioneering entity in the field of fully human antibody drug development. With operational footprints in Beijing, Haimen Jiangsu, Shanghai, and Boston (Waltham), our company is charting new frontiers in biotechnology.

My expertise encompasses a wide spectrum, including immunology, autoimmune diseases such as asthma, colitis, and multiple sclerosis, as well as mouse gene-targeting, infectious disease research, and antibody drug development.